NEEDHAM, Mass., Nov. 02, 2016 -- TripAdvisor, Inc. (NASDAQ:TRIP), the world's largest travel site*, today announced that its President and Chief Executive Officer Steve Kaufer will participate in the following conferences during the month of November:
RBC Capital Markets Technology, Internet, Media and Telecommunications Conference
at 8:50 a.m. Eastern Time Thursday, November 10, 2016 in New York, NY. The presentation will be audiocast at http://ir.tripadvisor.com/events.cfm. Replay of the audio webcast will be available for at least 30 days.
Liberty TripAdvisor Holdings Investor Meeting at approximately 10:25 a.m. Eastern Time on Thursday, November 10, 2016 in New York, NY. A live audiocast of the presentation will be available to the public on the Liberty TripAdvisor Holdings IR site http://ir.libertytripadvisorholdings.com/events-presentations. Replay of the audio webcast will be available for 30 days.
Phocuswright Conference Center Stage Executive Interview at approximately 3:10 p.m. Pacific Time on Wednesday, November 16, 2016 in Los Angeles, California. To access the presentations, register for a complimentary online conference ticket by visiting http://phocuswrightconference.com/streaming. Presentations can be viewed real-time or accessed on-demand through March 2017.
About TripAdvisor
TripAdvisor® is the world's largest travel site*, enabling travelers to unleash the full potential of every trip. TripAdvisor offers advice from millions of travelers and a wide variety of travel choices and planning features with seamless links to booking tools that check hundreds of websites to find the best hotel prices. TripAdvisor branded sites make up the largest travel community in the world, reaching 350 million average monthly unique visitors**, and reached 385 million reviews and opinions covering 6.6 million accommodations, restaurants and attractions. The sites operate in 48 markets worldwide. TripAdvisor: Know better. Book better. Go better.
TripAdvisor, Inc. (TRIP), through its subsidiaries, manages and operates websites under 24 other travel media brands: www.airfarewatchdog.com, www.bookingbuddy.com, www.citymaps.com, www.cruisecritic.com, www.familyvacationcritic.com, www.flipkey.com, www.thefork.com (including www.lafourchette.com, www.eltenedor.com, www.iens.nl and www.dimmi.com.au), www.gateguru.com, www.holidaylettings.co.uk, www.holidaywatchdog.com, www.housetrip.com, www.independenttraveler.com, www.jetsetter.com, www.niumba.com, www.onetime.com, www.oyster.com, www.seatguru.com, www.smartertravel.com, www.tingo.com, www.travelpod.com, www.tripbod.com, www.vacationhomerentals.com, www.viator.com, and www.virtualtourist.com.
*Source: comScore Media Metrix for TripAdvisor Sites, worldwide, May 2016
**Source: TripAdvisor log files, Q2 2016
Contacts Investors (781) 800.5561 [email protected] Media (781) 800.5237 [email protected]


Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



